Ngā hua rapu - Vincent A. Miller

Whakamahine hua
  1. 1
    High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

    High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer mā Jennifer Clarke, William Pao, Nian Wu, Vincent A. Miller, Andrew B. Lassman

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

    New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer mā Geoffrey R. Oxnard, Maria E. Arcila, Juliann Chmielecki, Marc Ladanyi, Vincent A. Miller, William Pao

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with <i>EGFR</i>-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

    Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with <i>EGFR</i>-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Cl... mā Jamie E. Chaft, Geoffrey R. Oxnard, Camelia S. Sima, Mark G. Kris, Vincent A. Miller, Gregory J. Riely

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with <i>EGFR</i>-Mutant Lung Adenocarcinoma

    Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with <i>EGFR</i>-Mutant Lung Adenocarcinoma mā James Bean, Gregory J. Riely, Marissa N. Balak, Jenifer L. Marks, Marc Ladanyi, Vincent A. Miller, William Pao

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling

    Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling mā Angel Qin, Adrienne Johnson, Jeffrey S. Ross, Vincent A. Miller, Siraj M. Ali, Alexa B. Schrock, Shirish M. Gadgeel

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping

    Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping mā Geoffrey R. Oxnard, Vincent A. Miller, Mark E. Robson, Christopher G. Azzoli, William Pao, Marc Ladanyi, Maria E. Arcila

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden

    Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden mā Victoria E. Wang, Anatoly Urisman, Lee A. Albacker, Siraj M. Ali, Vincent A. Miller, Rahul Aggarwal, David M. Jablons

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Phosphatidylinositol 3‐kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities

    Phosphatidylinositol 3‐kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities mā Sherri Z. Millis, Denis L. Jardim, Lee A. Albacker, Jeffrey S. Ross, Vincent A. Miller, Siraj M. Ali, Razelle Kurzrock

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

    Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain mā William Pao, Vincent A. Miller, Katerina Politi, Gregory J. Riely, Romel Somwar, Maureen F. Zakowski, Mark G. Kris, Harold Varmus

    I whakaputaina 2005
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring <i>BRAF</i> Mutations

    Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring <i>BRAF</i> Mutations mā Paul K. Paik, Maria E. Arcila, Michael Fara, Camelia S. Sima, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Gregory J. Riely

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study

    Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study mā Vineeta Agarwala, Sean Khozin, Gaurav Singal, Claire O’Connell, Deborah Kuk, Gerald Li, Anala Gossai, Vincent A. Miller, Amy P. Abernethy

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors

    Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors mā Darren Sigal, Munveer S. Bhangoo, Jonathan A. Hermel, Dean C. Pavlick, Garrett M. Frampton, Vincent A. Miller, Jeffrey S. Ross, Siraj M. Ali

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

    Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation mā Geoffrey R. Oxnard, Maria E. Arcila, Camelia S. Sima, Gregory J. Riely, Juliann Chmielecki, Mark G. Kris, William Pao, Marc Ladanyi, Vincent A. Miller

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    EGFR Mutations in Lung Adenocarcinomas

    EGFR Mutations in Lung Adenocarcinomas mā Allan R. Li, Dhananjay Chitale, Gregory J. Riely, William Pao, Vincent A. Miller, Maureen F. Zakowski, Valerie W. Rusch, Mark G. Kris, Marc Ladanyi

    I whakaputaina 2008
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib

    Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib mā Melissa L. Johnson, Greg J. Riely, Naiyer A. Rizvi, Christopher G. Azzoli, Mark G. Kris, Camelia S. Sima, Michelle S. Ginsberg, William Pao, Vincent A. Miller

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

    Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers mā Aaron M. Goodman, Shumei Kato, Lyudmila Bazhenova, Sandip Pravin Patel, Garrett M. Frampton, Vincent A. Miller, Philip J. Stephens, Gregory A. Daniels, Razelle Kurzrock

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies

    Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies mā Aaron M. Goodman, Shumei Kato, Philip R. Cohen, Amélie Boichard, Garrett M. Frampton, Vincent A. Miller, Philip J. Stephens, Gregory A. Daniels, Razelle Kurzrock

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

    Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer mā Vincent A. Miller, James R. Rigas, Prudence A. Francis, Stefan C. Grant, Katherine M.W. Pisters, Mark G. Kris, Karen Woolley, Ennapadam Venkatraman, Robert T. Heelan

    I whakaputaina 1995
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

    KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib mā William Pao, Theresa Y. Wang, Gregory J. Riely, Vincent A. Miller, Qiulu Pan, Marc Ladanyi, Maureen F. Zakowski, Robert T. Heelan, Mark G. Kris, Harold Varmus

    I whakaputaina 2005
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors

    Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors mā Jennifer J. Wheler, Johnique T. Atkins, Filip Janků, Stacy L. Moulder, Philip J. Stephens, Roman Yelensky, Vicente Valero, Vincent A. Miller, Razelle Kurzrock, Funda Meric‐Bernstam

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: